We discovered that platypus and echidna express a single GLP-1 peptide in both intestine and venom
[4] [5] Appropriate clinical management for patients with comorbid metabolic conditions and problematic alcohol use should include: Comprehensive assessment of alcohol consumption patterns using validated screening tools (AUDIT, AUDIT-C) Referral to addiction medicine specialists or behavioral health providers for evidence-based AUD treatment, especially with red flags such as history of severe withdrawal, seizures, delirium tremens, pregnancy, severe liver disease, or suicidality Consideration of FDA-approved pharmacotherapies for alcohol use disorder (naltrexone, acamprosate, disulfiram) with attention to their specific contraindications [9] [11] If GLP-1 therapy is indicated for diabetes or obesity, close monitoring for changes in alcohol consumption and related behaviors Patient education emphasizing that any effects on alcohol cravings are not established therapeutic benefits Regular follow-up to assess medication adherence, adverse effects, and overall treatment response Patients should never discontinue evidence-based treatments for alcohol use disorder in favor of unproven approaches
But when food intake is limited, prioritizing soluble fiber tends to produce better results because it directly addresses the primary problem, stool that has become too hard and dry
I suspect the pill will be priced somewhere around about 80 to start with, progressing to 130 [for the intermediate dose], and maybe 160 for the top dose. With other drug companies developing their own weight-loss pills, however, competition could also drive down the costs of treatment, as first-generation drugs, or those that offer slightly poorer top-line results, command lower prices, said The Economist
In the SAVOR TIMI 53 trial, saxagliptin had no significant difference compared to placebo in the rate of ischemic events
